SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-19
👔
Calidi Biotherapeutics, Inc.
@CLDI_InsiderForm 4 Filing: Fernandez Santidrian Antonio Acquires (Grant) shares of $CLDI
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
Calidi Biotherapeutics, Inc.
Ticker: $CLDI
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-08-17
Shares: 16,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Fernandez Santidrian Antonio, holds the title of Chief Scientific Officer at Calidi Biotherapeutics, Inc..
On 2026-08-17, the insider transacted 16,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Fernandez Santidrian Antonio (Chief Scientific Officer) was granted $0 of $CLDI
Post-Transaction Position: 16,000 shares
SEC Accession No: 0001493152-26-039286 (CIK: 1990403)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.